- |||||||||| Tai'ai (telitacicept) / Rongchang Pharma
Review, Journal: The Latest Progress in the Application of Telitacicept in Autoimmune Diseases. (Pubmed Central) - Dec 12, 2024 So far, the efficacy and safety of telitacicept in autoimmune diseases have been fully demonstrated in clinical practice. There are still many unresolved issues regarding the timing of initiation and discontinuation, still needs to be evaluated in future studies.
- |||||||||| Tai'ai (telitacicept) / Rongchang Pharma, Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Review, Journal: Neuromyelitis optica spectrum disorder with ultra-longitudinally extensive transverse myelitis: A case report and literature review. (Pubmed Central) - Nov 19, 2024 Simultaneously, sequential disease-modifying therapy was initiated, starting with long-term oral administration of mycophenolate mofetil, followed by cyclophosphamide, telitacicept, and Inebilizumab...Early and comprehensive evaluation of autoimmune diseases is crucial in patients with NMOSD presenting with u-LETM as the initial symptom. Prompt treatment initiation, followed by disease-modifying therapy, is essential for improving patient prognosis.
- |||||||||| Tai'ai (telitacicept) / Rongchang Pharma
Enrollment closed, Trial completion date, Trial primary completion date: A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) (clinicaltrials.gov) - Nov 18, 2024 P3, N=350, Active, not recruiting, Prompt treatment initiation, followed by disease-modifying therapy, is essential for improving patient prognosis. Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Mar 2027 | Trial primary completion date: Jun 2025 --> Jan 2027
- |||||||||| Aidixi (disitamab vedotin) / Pfizer
Biomarker, Journal, Real-world evidence, Real-world: Real-world application of disitamab vedotin (RC48-ADC) in patients with (Pubmed Central) - Nov 18, 2024 Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Mar 2027 | Trial primary completion date: Jun 2025 --> Jan 2027 RC48-ADC showcases promising efficacy and manageable safety in patients with both HER2-positive and HER2-low-expression mBC.
- |||||||||| Review, Journal: Antibody-Drug Conjugates in Breast Cancer: Toward a Molecular Perspective Into Clinical Practice. (Pubmed Central) - Oct 30, 2024
ADCs represent a promising frontier in precision cancer treatment, with continued research enhancing their potential in breast cancer and beyond. This review provides a comprehensive exploration of ADCs' evolution in breast cancer therapy, offering a molecular perspective to inform clinical practice and update colleagues on this dynamic field.
- |||||||||| AiTan (rivoceranib) / HLB Bio Group, Aidixi (disitamab vedotin) / Pfizer
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature. (Pubmed Central) - Oct 30, 2024 Despite the unfavorable prognosis associated with advanced GC, the implementation of personalized treatment approaches may still prove beneficial for select patients. In patients with HER2-positive GC with extensive metastatic involvement, the use of the HER2-targeted combination with apatinib has demonstrated the potential to prolong both PFS and overall survival.
- |||||||||| Aidixi (disitamab vedotin) / Pfizer
Journal, IO biomarker: FOXA1, induced by RC48, regulates HER2 transcription to enhance the tumorigenic capacity of lung cancer through PI3K/AKT pathway. (Pubmed Central) - Oct 23, 2024 Recently, the HER2-targeting antibody drug Disitamab vedotin (RC48) was approved and introduced primarily for gastric and bladder cancers, with minimal investigation in the field of lung cancer...In clinical specimens, heightened expressions of FOXA1 and HER2 correlate positively with clinical progression and poorer prognosis. These findings suggest that FOXA1 may serve as a potential biomarker or therapeutic target in future non-small cell lung cancer (NSCLC) treatments, and ongoing research may position RC48 as a transformative agent in lung cancer therapy.
- |||||||||| Tai'ai (telitacicept) / Rongchang Pharma
Trial completion date, Trial primary completion date, Real-world evidence, Compliance, Real-world: Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Oct 1, 2024 P=N/A, N=139, Recruiting, The current findings imply the potential efficacy of HER2-targeted ADCs for patients with HER2-low metastatic EC. Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Oct 2024
- |||||||||| Benlysta (belimumab) / GSK, Tai'ai (telitacicept) / Rongchang Pharma
Comparison of Efficacy and Safety Between Belimumab and Telitacicept in the Treatment of Systemic Lupus Erythematosus (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3459; Recruiting --> Active, not recruiting Belimumab or telitacicept combined with standard treatment significantly improved disease activity in SLE patients but with no difference in efficacy.The incidence of infection with belimumab is relatively low, and the upper respiratory tract infection of telitacicept is more common.
- |||||||||| Fabhalta (iptacopan) / Novartis, Tai'ai (telitacicept) / Rongchang Pharma, atacicept (VT-001) / Vera Therap
Comparative Efficacy and Safety of New Therapies for IgA Nephropathy: A Systematic Review and Network Meta-Analysis (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_3160; Conclusion RC28-E demonstrated efficacy and tolerability comparable with those of conbercept in DME. This systematic review and network meta-analysis indicate Mycophenolate and Telitacicept are most effective in reducing UPCR and improving eGFR, suggesting these as preferable treatments for IgAN patients.
- |||||||||| Tai'ai (telitacicept) / Rongchang Pharma
Trial completion date, Trial primary completion date: A Study of Telitacicept in Lupus Nephritis (clinicaltrials.gov) - Sep 22, 2024 P2, N=120, Recruiting, Participant recruitment and exclusion flowchart. Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- |||||||||| Tai'ai (telitacicept) / Rongchang Pharma
Trial completion date, Trial primary completion date: A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 22, 2024 P1, N=12, Recruiting, Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Dec 2025 Trial completion date: Dec 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Sep 2025
|